Site - Press Release Archive Press Release Archive 1998-2005 Keyword Search Year All202320222021202020192018201720162015201420132012201120102009200820072006 Oct 02 2023 Cytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting Sep 28 2023 Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program Sep 07 2023 Cytokinetics to Participate in Upcoming Investor Conferences Sep 06 2023 Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy Sep 01 2023 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 03 2023 Cytokinetics Reports Second Quarter 2023 Financial Results Aug 01 2023 Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) Jul 27 2023 Cytokinetics to Announce Second Quarter Results on August 3, 2023 Jul 05 2023 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 20 2023 Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Jun 02 2023 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Jun 01 2023 Cytokinetics to Participate in Upcoming Investor Conferences May 20 2023 Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress May 15 2023 Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress May 11 2023 Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586 May 08 2023 Cytokinetics to Participate in the JMP Securities Life Sciences Conference May 04 2023 Cytokinetics Reports First Quarter 2023 Financial Results May 03 2023 Cytokinetics to Hold Annual Meeting of Stockholders May 01 2023 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 20 2023 Cytokinetics to Announce First Quarter Results on May 4, 2023 Apr 10 2023 Cytokinetics To Participate In The 22nd Annual Needham Virtual Healthcare Conference Apr 03 2023 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 31 2023 Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis Mar 27 2023 Cytokinetics Releases Inaugural Corporate Responsibility Report Mar 06 2023 Cytokinetics to Participate in Upcoming Investor Conferences Mar 04 2023 Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session Mar 02 2023 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 01 2023 Cytokinetics Reports Fourth Quarter 2022 Financial Results Feb 28 2023 Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil Feb 24 2023 Cytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific Session Feb 22 2023 Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day Feb 15 2023 Cytokinetics to Announce Fourth Quarter Results on March 1, 2023 Feb 01 2023 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 30 2023 Cytokinetics Announces Recipients of Its Fifth Annual Communications Grant Program Jan 04 2023 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 03 2023 Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
